Sažetak
[Objective] To observe the expression levels of serum soluble Triggering Receptor Expressed on Myeloid cells-1 (sTREM-1) and serum soluble Human Leukocyte Antigen-DR (sHLA-DR) in patients with atrial fibrillation (AF) and their clinical significance.
[Methods] 136 patients with atrial fibrillation who were admitted from April 2023 to September 2025 were selected as the research group, and 100 healthy individuals who underwent physical examinations during the same period were selected as the control group. The serum levels of sTREM-1 and sHLA-DR were detected by ELISA, and the serum levels of interleukin-6 (IL-6) and C-reactive protein (CRP) were measured by an automatic biochemical analyzer.
[Results] The study group exhibited elevated blood levels of sTREM-1 and sHLA-DR in comparison to the control group (P < 0.05). Regarding patient age, sex, type of atrial fibrillation, and EHRA classification, there were statistically significant variations in the blood levels of sTREM-1 and sHLA-DR between the study group and the control group (P < 0.05). The study group had greater levels of CRP and serum IL-6 than the control group (P < 0.05). The expression levels of sTREM-1 and sHLA-DR in the serum were shown to be favorably linked with those of IL-6 and CRP (P < 0.05) using Pearson correlation analysis. Serum levels of the inflammatory markers IL-6 and CRP, as well as sTREM-1 and sHLA-DR, were found to be strongly associated with AF, according to the results of the logistic regression analysis.
[Conclusion] Serum levels of sTREM-1 and sHLA-DR are increased in patients with atrial fibrillation, which may be related to the onset and progression of AF. Clinically, these can be considered relevant biological indicators for monitoring the condition of AF.
Ključne reči
Array
Array
Array
Reference
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.